Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Lovly CM, Pao W
Sci Transl Med. 2012 4 (120): 120ps2

PMID: 22323827 · DOI:10.1126/scitranslmed.3003728

Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.

MeSH Terms (8)

Anaplastic Lymphoma Kinase Crizotinib Humans Lung Neoplasms Protein Kinase Inhibitors Pyrazoles Pyridines Receptor Protein-Tyrosine Kinases

Connections (3)

This publication is referenced by other Labnodes entities: